JW Shinyak
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
JW Shinyak is a South Korean pharmaceutical company that develops and supplies prescription medicines and related health-care products.
Its customers are broadly the hospitals, clinics, and pharmacies that make up the domestic health-care supply chain. The company is listed on KOSDAQ, Korea's tech and small-cap exchange, and operates as a standalone pharmaceutical business following the liquidation of its only consolidated subsidiary.
Summary is AI-generated and may contain errors · figures from DART filings
The filing notes that JW Shinyak absorbed the former JW Creagen subsidiary, which has since been fully liquidated, leaving the company with no remaining consolidated subsidiaries.
JW Shinyak in five facts
What does JW Shinyak do?
JW Shinyak is a South Korean pharmaceutical company that develops and supplies prescription medicines and related health-care products.
Where is JW Shinyak listed and in which sector?
JW Shinyak (Korean name: JW신약) trades under KRX code 067290 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is JW Shinyak?
Its market capitalisation was US$108.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were JW Shinyak's latest annual revenue and operating profit?
For fiscal year 2025, JW Shinyak reported revenue of US$61.2M, operating profit of US$5.6M and net income of US$11.8M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 12.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (preliminary) (fair disclosure)
JW Shinyak filed provisional (unaudited) separate results for Q2 2026: revenue of US$15.2M (+9.4% year on year), operating profit of US$2.53M (+34.1% year on year) and net income of US$2.52M (+15% year on year).
Earnings · Aug 12 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · May 22
- Material event report (convertible bonds)
JW Shinyak disclosed convertible bonds to raise US$9.97M, about 9.1% of its market value.
Capital raise · May 21 - Operating results (preliminary) (fair disclosure)
JW Shinyak filed provisional (unaudited) separate results for Q1 2026: revenue of US$14.4M (+8.8% year on year), operating profit of US$1.94M (+332.1% year on year) and net income of US$1.79M (−68.9% year on year).
Earnings · May 13 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
JW Shinyak updated its previously filed consolidated results for FY2025: revenue of US$54.8M (−12.87% year on year), operating profit of US$5.04M (−25.09% year on year) and net income of US$10.6M (+208.39% year on year).
Earnings · Mar 6 · 2 versions